{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.0"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"10"}],"units":"Participants"}],"description":"A complete response was defined as the disappearance of the original monoclonal protein from the blood and urine on at least 2 determinations 6 weeks apart; \\< 5% plasma cells in the bone marrow on at least 2 determinations 6 weeks apart; if a skeletal survey is available, no increase in the size or number of lytic bone lesions; and the disappearance of soft tissue plasmacytomas for at least 6 weeks. A partial response was defined as a ≥ 50% reduction of monoclonal protein in the blood on at least 2 determinations 6 weeks apart; if present, reduction in 24-hour urinary light chain excretion by either ≥ 90% or to \\< 200 mg for at least 2 determinations 6 weeks apart; ≥ 50% reduction in the size of tissue plasmacytomas for at least 6 weeks; and if a skeletal survey is available, no increase in the size or number of lytic bone lesions.","groups":[{"description":"Participants received bevacizumab 5 mg/kg intravenously every 2 weeks for 6 months until disease progression or termination of the study. Participants showing a continuous benefit of therapy could receive treatment for a maximum of 12 months.","id":"OG000","title":"Bevacizumab 5 mg/kg"}],"paramType":"NUMBER","populationDescription":"Intent-to-treat population: All participants who received at least 1 dose of study drug.","reportingStatus":"POSTED","timeFrame":"Baseline to the end of the study (up to 1 year)","title":"Percentage of Participants With a Complete Response or a Partial Response","type":"PRIMARY","unitOfMeasure":"Percentage of participants"}